PNI-positive patients without radiotherapy had worse survival, while those receiving radiotherapy had outcomes comparable to patients without PNI.
Extratumoral perineural invasion predicted poorer survival, while microscopic versus macroscopic extranodal extension did not meaningfully separate outcomes.
Hydrogel spacers showed no meaningful loss of geometry during prostate SBRT, supporting stable rectal separation across the treatment course.
Intent to leave was reported by 51.7%, with team culture, wellbeing and career development independently associated with retention.
Larger irradiated bowel volumes predicted acute diarrhea after both short-course total neoadjuvant treatment and chemoradiation, although discrimination was modest.
Among patients under 70, twice-daily chemoradiotherapy was associated with 36.0 versus 22.2 months median survival, without higher acute toxicity.
Patients generally expected high radiotherapy benefit, but expectations of benefit and adverse events were not significantly correlated.
ERI-guided escalation to 60.1 Gy produced a 21.9% complete response rate in patients predicted to respond poorly.
The model retained moderate discrimination for recurrence and metastasis, but predicted non-cancer death less reliably, especially in older patients.
In a randomized US survey, “radiation therapy” reduced selection of the same treatment by 8.3 percentage points versus “radiotherapy.”
A single 7 Gy fraction delivered 20–28 hours before hip arthroplasty produced similar heterotopic ossification rates to postoperative diclofenac.
Retroverted uterine position increased rectal and bowel dose during cervical brachytherapy, but survival, recurrence and severe toxicity remained comparable.
The OSCAR workflow delivered the first urgent or palliative fraction without planning CT in approximately 1 hour 50 minutes.
Single-fraction 22 Gy SRS achieved higher one-year local control than 20 Gy, although retrospective dose selection creates important confounding.
Retrospective outcomes with carboplatin-paclitaxel were not significantly different from cisplatin, supporting its use when cisplatin is contraindicated.